Assessment of lipid profile in patients with fatty liver disease.
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2023/06/054482
- Lead Sponsor
- Tushar Akare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 105
Evidence of fatty liver on ultrasonography of abdomen.
Patients who satisfy the European Association for the Study of the Liver Criteria (EASL criteria) for NAFLD will be recruited for the study.
EASL criteria for NAFLD is alcohol consumption less than 30 g/day for men and less than 20 g/day for women.
Age >18 years and <65 years of any gender.
Subjects having significant alcohol consumption (more than 30 gm/day in case of males and more than 20 gm/day in case of females)
Pregnant or lactating women
Subjects carrying hepatitis B and/or hepatitis C virus infection
Patients with autoimmune hepatic disease
Other chronic hepatic diseases i.e. Wilson’s disease, hereditary hemochromatosis, primary billiary cirrhosis etc.
Patients on drugs that can lead to fatty liver e.g. methotrexate, amiodarone, anti- retroviral drugs, tamoxifene, barium salts, tetracycline, Estrogen, glucocorticoids, etc.
Individuals having DM, metabolic syndrome, dyslipidemia and/or hypothyroidism
Individuals having significant alcohol consumption and/or CLD
Pregnant or lactating women.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting triglyceride <br/ ><br>Fasting glucose <br/ ><br>Triglyceride glucose index <br/ ><br>Liver ElastographyTimepoint: Baseline
- Secondary Outcome Measures
Name Time Method Severity of diseaseTimepoint: Baseline